Prof Michael Good AO received support from NFMRI from 2015 to 2018 to support the production and testing of a GMP-grade peptide conjugate vaccine to prevent infection with group A streptococcus – the causative agent of tonsillitis, deep tissue sepsis, pyoderma and rheumatic heart disease.
The prevalence of severe Group A Streptococcus related disease is estimated to be greater than 18 million cases globally, with 1.7 million new cases each year.
Despite the project only commencing in early 2015, support from the Foundation has already assisted Professor Good and his team to attract the interest of a multinational pharmaceutical company.
The project has also attracted additional funding with clinical trials commencing in Australia and Canada in 2020.
